This company has been marked as potentially delisted and may not be actively trading. Antares Pharma (ATRS) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ATRS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Best Healthcare Penny StocksSeptember 18, 2024 | benzinga.comAntares Vision SpA AVJanuary 23, 2024 | morningstar.comMAntares Vision Share Price (AV.MI)December 7, 2023 | lse.co.ukAprea Therapeutics’ Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy’s Buy RatingOctober 19, 2023 | markets.businessinsider.comAntares Reaches New 52-Week High (AIS)September 3, 2023 | thestreet.comAntares Vision SpA (ANV)August 2, 2023 | investing.comCOP Syringes Market Competitive Situation By 2030April 27, 2023 | marketwatch.comPharma Track and Trace Solutions Market Trends By 2031April 6, 2023 | marketwatch.comTransdermal Patch Drug Delivery System Market Size, Share, Demand, Opportunity, Outlook, Trends, Revenue, and Future Growth 2027March 28, 2023 | marketwatch.comDrug Transport Technology Market Top Players By 2031March 26, 2023 | marketwatch.comDrug Delivery Technology Market 2023 Size and Forecast to 2030March 24, 2023 | marketwatch.comPharma Track and Trace Solutions Market Forecast 2023 To 2029 Size, Global Predictive AnalyticsMarch 4, 2023 | marketwatch.comGlobal Genitourinary Drugs Market Report 2022 to 2027: Featuring Allergan, Antares Pharma, Bayer and Novartis Among OthersFebruary 17, 2023 | yahoo.comPharma Track and Trace Solutions Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 ImpactJanuary 4, 2023 | marketwatch.comPharma Track and Trace Solutions Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028December 16, 2022 | marketwatch.comDrug Delivery Technology Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2030December 1, 2022 | marketwatch.comPharmaceutical Drug Delivery Global Market Report 2022September 14, 2022 | yahoo.comPharma Track and Trace Solutions Market Report Detailed Market Analysis and Forecasts 2022 To 2028 | 112 Pages ReportAugust 20, 2022 | marketwatch.comLooking Into Antares Pharma's Return On Invested CapitalJune 8, 2022 | msn.comAntares Pharma (Nasdaq:ATRS) HeadlineTrading was temporarily halted for "ATRS" at 07:05 PM with a stated reason of "News pending."...May 24, 2022 | marketbeat.comHalozyme: Antares Pharma Bolsters Growth ProspectsMay 19, 2022 | seekingalpha.comMiMedx Group and Inozyme Stock See Action From Activist InvestorsMay 6, 2022 | finance.yahoo.comHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAApril 26, 2022 | finance.yahoo.comLooking Into Antares Pharma Inc's Recent Short InterestApril 14, 2022 | benzinga.comAntares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?April 14, 2022 | finance.yahoo.comAntares Pharma to be acquired by Halozyme in $960M dealApril 13, 2022 | finance.yahoo.comWhy Is Antares Pharma (ATRS) Stock Up Today?April 13, 2022 | investorplace.comAntares Pharma stock rockets after Halozyme buyout deal for a near-50% premiumApril 13, 2022 | morningstar.comMWhy Antares Pharma Stock Is Bolting Higher TodayApril 13, 2022 | fool.comAntares Pharma Announces FDA Approval Of TLANDO(TM), an Oral Treatment for Testosterone Replacement TherapyMarch 29, 2022 | stockhouse.comThe Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For AkebiaMarch 29, 2022 | msn.comAntares wins full FDA approval for testosterone replacement therapyMarch 29, 2022 | seekingalpha.comAntares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyMarch 29, 2022 | finance.yahoo.comAntares Pharma's Return On Capital Employed OverviewMarch 8, 2022 | benzinga.comAntares Pharma (ATRS) Investor Presentation - SlideshowMarch 8, 2022 | seekingalpha.comZacks Investment Research Upgrades Antares Pharma (NASDAQ:ATRS) to HoldMarch 7, 2022 | marketbeat.comAntares Pharma: Q4 Earnings SnapshotMarch 3, 2022 | apnews.comAAntares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsMarch 3, 2022 | finance.yahoo.comAntares Pharma (ATRS) Surpasses Q4 Earnings and Revenue EstimatesMarch 3, 2022 | finance.yahoo.comSmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue EstimatesFebruary 28, 2022 | finance.yahoo.comAntares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceFebruary 28, 2022 | finance.yahoo.comAntares Pharma (NASDAQ:ATRS) Could Easily Take On More DebtFebruary 18, 2022 | finance.yahoo.comHenry Schein (HSIC) Q4 Earnings and Revenues Beat EstimatesFebruary 15, 2022 | finance.yahoo.comHere's Why I Think Antares Pharma (NASDAQ:ATRS) Might Deserve Your Attention TodayJanuary 13, 2022 | nasdaq.comAntares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?January 13, 2022 | finance.yahoo.comAntares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesJanuary 12, 2022 | finance.yahoo.comAntares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueJanuary 11, 2022 | finance.yahoo.comMedMira strengthen its Board with New AppointmentDecember 17, 2021 | finance.yahoo.comAssertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44MDecember 16, 2021 | markets.businessinsider.comIf You Like EPS Growth Then Check Out Antares Pharma (NASDAQ:ATRS) Before It's Too LateDecember 8, 2021 | finance.yahoo.com Get Antares Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRS Media Mentions By Week ATRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRS News Sentiment▼0.000.90▲Average Medical News Sentiment ATRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRS Articles This Week▼00▲ATRS Articles Average Week Get Antares Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HAE News ICUI News XRAY News QDEL News NEOG News STAA News CERS News OSUR News UTMD News ANIK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antares Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
